DRIVEN BY SCIENCE INSPIRED BY HOPE

Dead / Abandoned — Abandoned — after publication (as of 02 Dec 2019)

What this means for you

This application is over — abandoned 02 Dec 2019. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
88424911
Mark type
Stylized text
Filed
10 May 2019
Published for opposition
08 Oct 2019
Abandoned
02 Dec 2019
Attorney of record
Devon E. White

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders

Owner

Prosecution history

  • 02 Dec 2019 — ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
  • 02 Dec 2019 — ABANDONMENT - AFTER PUBLICATION
  • 26 Nov 2019 — TEAS EXPRESS ABANDONMENT RECEIVED
  • 28 Oct 2019 — EXTENSION OF TIME TO OPPOSE RECEIVED
  • 08 Oct 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 08 Oct 2019 — PUBLISHED FOR OPPOSITION
  • 18 Sept 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 05 Sept 2019 — ASSIGNED TO LIE
  • 02 Sept 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 30 Aug 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 30 Aug 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 30 Aug 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 01 Aug 2019 — NOTIFICATION OF PRIORITY ACTION E-MAILED
  • 01 Aug 2019 — PRIORITY ACTION E-MAILED
  • 01 Aug 2019 — PRIORITY ACTION WRITTEN

View this trademark record on Marksy